Exelixis, Inc. (NASDAQ:EXEL) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET

Company Participants

Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations

Michael Morrissey - President and Chief Executive Officer

Christopher Senner - Executive Vice President and Chief Financial Officer

P.J. Haley - Executive Vice President, Commercial

Dana Aftab - Chief Scientific Officer

Vicki Goodman - Chief Medical Officer

Peter Lamb - Chief Scientific Officer

Conference Call Participants

Asthika Goonewardene - Truist

Jason Gerberry - Bank of America Securities

Michael Schmidt - Guggenheim

Andy Hsieh - William Blair

Jay Olson - Oppenheimer

Silvan Tuerkcan - JMP Securities

Etzer Darout - BMO Capital Markets

Derek Archila - Wells Fargo

Joseph Catanzaro - Piper Sandler

Jeffrey Hung - Morgan Stanley

Alex Bouilloux - Barclays

Stephen Willey - Stifel

Chris Shibutani - Goldman Sachs

Yaron Werber - TD Cowen

Operator

Good day, ladies and gentlemen, and welcome to the Exelixis Secod Quarter 2023 Financial Results Conference Call. My name is Tawanda and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. You may begin.

Susan Hubbard

Thank you, Tawanda, and thank you all for joining us for the Exelixis second quarter 2023 financial results conference call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; Dana Aftab, our Chief Scientific Officer; and Vicki Goodman, our Chief Medical Officer, who will review our progress for the second quarter 2023 ended June 30th, 2023. Peter Lamb, our EVP of Scientific Strategy will join us for the Q&A portion of the call.

During the call today, we will be making financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release which is posted on our website for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving those measures from our GAAP results.

During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial, and strategic matters.

Actual events or results could of course differ materially. We refer you to the documents we filed from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of costs associated with discovery, product development, business development and commercialization activities.